Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 336 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR How to Provide Support as a Long-Distance Cancer Caregiver January 25, 2021 Prostate Cancer December 9, 2019 Despite Proven Safety of HPV Vaccines, More Parents Have Concerns October 22, 2021 Farmer With Stage IV Cancer Is Too Sick To Harvest Crops... January 23, 2020 Load more HOT NEWS FDA Approves Imetelstat for Low- To Intermediate-1 Risk Myelodysplastic Syndromes with... Got the COVID Blues? FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated...
